WeVote
Log In

Bill

Bill

S 3904

Prohibits procurement of opioid antidotes from certain entities.

2026-2027 Regular Session Introduced by Angela McKnight

New Jersey bill prohibits state procurement of opioid antidotes from unspecified entities, potentially affecting naloxone availability for emergency and harm-reduction programs.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
0
WeVote Research Nonpartisan
Bill Summary · S 3904

Legislative bill overview

S 3904 prohibits New Jersey state procurement of opioid antidotes (primarily naloxone/Narcan) from specified entities, likely targeting manufacturers or distributors based on pricing, conduct, or other criteria. The bill was introduced by Senator Angela McKnight and referred to the health committee in March 2026, but specific excluded entities are not detailed in the available information.

Why is this important

Opioid antidotes are critical public health tools used in emergency response to overdoses. Procurement restrictions could affect the availability, cost, and distribution of naloxone to first responders, hospitals, and community programs. The policy signals potential accountability measures against opioid industry actors but requires clarity on which entities are targeted and why.

Potential points of contention

  • Unclear scope: Without knowing which specific entities are prohibited, it's difficult to assess whether the restriction targets legitimate public health goals or creates unintended market disruptions
  • Supply chain impacts: Limiting suppliers could reduce competition, potentially raising costs or creating shortages for emergency responders and harm-reduction programs
  • Coordination with federal policy: State procurement restrictions may conflict with existing federal contracts or create complications for interstate emergency response efforts

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.